Direct-to-consumer (DTC) marketing of pharmaceuticals has grown increasingly in the past decade. The American public views prescription drug advertising for a wide range of medical conditions, including high cholesterol, depression, allergies, and erectile dysfunction. The Federal Food and Drug Administration (FDA) regulates the content of these advertisements. Critics also have taken the position that the advertisements garner unearned trust from the public, are misleading, and promote unnecessary use of prescription drugs for common problems associated with aging. Proponents counter that DTC ads help eliminate stigmas associated with certain medical conditions, give patients an active role in their health care management, and encourages the doctor/patient relationship.
To do this, it is important to consider the ethical issues pertaining to these tactics. Numerous ethical dilemmas exist when examining the pharmaceutical industry’s tactics. This paper will serve to examine a mere few of these examples. Today’s world of medicine is dominated by industry, as physicians and patients alike rely on pharmaceutical companies to provide medications that address patient health concerns. Pharmaceutical companies intend to profit from the d... ... middle of paper ... .../147318/100,000_americans_die_each_year_from_prescription_drugs,_while_pharma_companies_get_rich>.
Kaphingst, K. A. (2004). A Content Analysis of Direct-to-ConsumerTelevision Prescription Drug Advertisements. Journal of Health Communication,Volume 9: , 515–528,. Office, U.
This paper will discuss two ethical issues surrounding longevity, the ethics of pharmaceutical companies associated with keeping us alive and comfortable, and the right to an individual’s definition of quality of life. The search for the fountain of youth has produced many multi-billion dollar corporations across the globe, from pharmaceutical companies to insurance agencies. The large profits these companies report yields incredible power and influence. Pharmaceutical conglomerates introduce new drugs worldwide targeted directly to those who are aging. Packaging is covered front to back with the fine print of the drugs’ possible side-affects, many sound more terrifying than actually just living with the condition.
These PBM companies compete against each other for contracts with employers and health plans. Thomas Gryta defines Pharmacy Benefit Managers as companies who “process prescriptions for the groups that pay for drugs, usually insurance companies or corporations, and use their size to negotiate with drug makers and pharmacies.” (2011) Pharmacy Benefit Managers serve as liaison between the paying companies and the health care system’s variables. Their revenue comes from service fees of processing prescriptions, managing mail-order pharmacies, and negotiating reduced costs with drug companies. This consolidation, along with others in the health services industry, factors a drive to cut costs and thus, increase revenues. By combining purchasing power and control over a large percentage of the drug industry, PBM’s can negotiate reductions in drug costs for themselves and their consumers.
Schacht, Wendy H., and John R. Thomas. Patent Law and Its Application to the Pharmaceutical Industry. Rep. no. RL30756. The Library of Congress, 10 Jan. 2005.
They serve as compliments to medical procedures; substitutes for surgery or other procedures; and new treatments where there were none previously (Oliver, Lee & Lipton, 2004). As the medical community’s understanding of the human body increases the possibility for new pharmaceutical interventions will increase. Prescription drug coverage is an important issue because many rely on the day to day help they receive from prescription drugs. Furthermore, the elderly and disabled populations are particularly reliant on prescription drugs and have some of the least means to purchase them (Huh, Rice & Ettner, 2008). The combination of limited income and high drug costs can cause people such as seniors to take risks with their health by trying to extend their medications or go without them.
2015;14:221-222. 7. Frank R .Lichtenberg,Pharmaceutical Innovation,Mortality Reduction,And Economic Growth,NBER, working paper Number .6569,may 1998,p1. 8. FRANK R. LICHTENBERG, The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982–2001, International Journal of Health Care Finance and Economics, 2005;5, 47–73.
The faster a company develops, markets, and distributes a product, the better chance they have at the monopoly of that product. If a drug company creates a new prescription drug for the treatment of Diabetes that no other company has created, a drug that treats a cause specific ailment, then that company will do anything to mass produce the product as to build rapport with consumers and obtain the monopoly for this particular drug therapy. Public pressu... ... middle of paper ... .... More people that take new drugs will result in greater numbers of adverse reactions. This is a statistical fact that will continue into the foreseeable future and one more bittersweet fact of pharmaceutical evolution. References Thomas J. Moore, AB., & Curt D Furberg, MD.
(2009). Developing solid oral dosage forms: Pharmaceutical theory and practice. London: Academic Press. Hilfiker, R. (2006). Polymorphism: In the pharmaceutical industry.